These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 22413748)
21. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. German P; Warren D; West S; Hui J; Kearney BP J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270 [TBL] [Abstract][Full Text] [Related]
22. Tenofovir disoproxil fumarate for the treatment of HIV infection. Pham PA; Gallant JE Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):459-69. PubMed ID: 16863446 [TBL] [Abstract][Full Text] [Related]
23. Lack of a significant drug interaction between raltegravir and tenofovir. Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763 [TBL] [Abstract][Full Text] [Related]
24. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037 [TBL] [Abstract][Full Text] [Related]
25. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study. Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679 [TBL] [Abstract][Full Text] [Related]
26. The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects. Behm MO; Yee KL; Liu R; Levine V; Panebianco D; Fackler P Clin Drug Investig; 2017 Jun; 37(6):571-579. PubMed ID: 28349328 [TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897 [TBL] [Abstract][Full Text] [Related]
28. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
35. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials. Godfrey AR; Digiacinto J; Davis MW Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241 [TBL] [Abstract][Full Text] [Related]
36. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. Kearney BP; Sayre JR; Flaherty JF; Chen SS; Kaul S; Cheng AK J Clin Pharmacol; 2005 Dec; 45(12):1360-7. PubMed ID: 16291710 [TBL] [Abstract][Full Text] [Related]
37. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. Blum MR; Chittick GE; Begley JA; Zong J J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400 [TBL] [Abstract][Full Text] [Related]
38. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Shaw JP; Sueoko CM; Oliyai R; Lee WA; Arimilli MN; Kim CU; Cundy KC Pharm Res; 1997 Dec; 14(12):1824-9. PubMed ID: 9453075 [TBL] [Abstract][Full Text] [Related]
39. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. Piscitelli S; Kim J; Gould E; Lou Y; White S; de Serres M; Johnson M; Zhou XJ; Pietropaolo K; Mayers D Br J Clin Pharmacol; 2012 Aug; 74(2):336-45. PubMed ID: 22288567 [TBL] [Abstract][Full Text] [Related]
40. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]